Stockreport

Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference

Upstream Bio, Inc.  (UPB) 
PDF WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc.  (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an [Read more]